Manu Mehta

Chandigarh, CH, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Validation of AGILE 3+ and AGILE 4 Scores for Assessing Advanced Fibrosis and Cirrhosis in Indian Patients With Nonalcoholic Fatty Liver Disease: An Indian Consortium on Non-alcoholic Fatty Liver Disease Study.

Validation of AGILE 3+ and AGILE 4 Scores for Assessing Advanced Fibrosis and Cirrhosis in Indian Patients With Nonalcoholic Fatty Liver Disease: An Indian Consortium on Non-alcoholic Fatty Liver Disease Study.

Journal: Journal of clinical and experimental hepatology

Published: December 03, 2025

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.

Journal: The Indian journal of medical research

Published: October 26, 2025

Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) Study.

Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) Study.

Journal: Journal of clinical and experimental hepatology

Published: October 12, 2025

Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.

Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.

Journal: Journal of hepatology

Published: May 15, 2024

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study.

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study.

Journal: Alimentary pharmacology & therapeutics

Published: October 29, 2023

Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.

Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.

Journal: Journal of clinical and experimental hepatology

Published: September 09, 2023

Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.

Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.

Journal: Journal of hepatology

Published: July 25, 2023

Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD.

Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD.

Journal: International journal of obesity (2005)

Published: March 15, 2023

Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.

Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.

Journal: Liver research (Beijing, China)

Published: February 17, 2022

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.

Journal: Metabolic syndrome and related disorders

Published: January 27, 2022

NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.

NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.

Journal: Journal of hepatology

Published: September 02, 2021

FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.

FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.

Journal: Journal of clinical and experimental hepatology

Published: March 24, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026